1972
DOI: 10.1016/0026-0495(72)90089-3
|View full text |Cite
|
Sign up to set email alerts
|

Estrogen-induced pancreatitis in patients with previously covert familial Type V hyperlipoproteinemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
25
0

Year Published

1973
1973
2014
2014

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 100 publications
(27 citation statements)
references
References 39 publications
2
25
0
Order By: Relevance
“…The present findings with low dosage dl-norgestrel in women with ovarian failure provide new insights into progestin effects on lipoprotein metabolism and may have implications both for the design of progestin-only and combined estrogen/ progestin oral contraceptives for premenopausal women and the formulation ofperhaps more widely acceptable continuous low dosage female hormonal replacement therapy in postmenopausal women (2), including those in whom moderate hypertriglyceridemia (46) may pose a risk of coronary heart disease and more severe hypertriglyceridemia may pose a risk ofestrogen-induced pancreatitis (47,48 …”
Section: Resultsmentioning
confidence: 99%
“…The present findings with low dosage dl-norgestrel in women with ovarian failure provide new insights into progestin effects on lipoprotein metabolism and may have implications both for the design of progestin-only and combined estrogen/ progestin oral contraceptives for premenopausal women and the formulation ofperhaps more widely acceptable continuous low dosage female hormonal replacement therapy in postmenopausal women (2), including those in whom moderate hypertriglyceridemia (46) may pose a risk of coronary heart disease and more severe hypertriglyceridemia may pose a risk ofestrogen-induced pancreatitis (47,48 …”
Section: Resultsmentioning
confidence: 99%
“…Except for case reports, [5][6][7][8][9][10] the epidemiologic data on the association between postmenopausal hormone replacement therapy and acute pancreatitis are sparse. Only 1 case-control study (n = 1054 cases of acute pancreatitis), 15 which used data from prescription databases and hospital registers in Denmark, has examined the risk of acute pancreatitis associated with current and past use of hormone replacement therapy (defined as a prescription for such therapy within 1-90 or 91-365 days, respectively).…”
Section: Discussionmentioning
confidence: 99%
“…Most case reports on estrogen-induced pancreatitis have reported concurrent hypertriglyceridemia. [7][8][9][10][11][12]14 Use of hormone replacement therapy may elevate triglycerides, 30 which, even at moderately elevated levels, have been associated with increased risk of acute pancreatitis. 31 The role of triglycerides in the pathogenesis of acute pancreatitis is not fully understood, but a key event is thought to be accumu lation of free fatty acids in the pancreas after hydrolysis of triglycerides by pancreatic lipase.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…There is a body of evidence to suggest that oestrogens are important in the normal functioning of the pancreas (Grossman et al, 1969;Sandberg & Rosenthal, 1979), and are implicated as a factor in pancreatic disease (Davidoff et al, 1973;Glueck et al, 1972;Greenberger et al, 1966). There is also evidence for the presence of the oestrogen receptor (ER) in normal pancreas and pancreatic cancer (Greenway et al, 1981) and for prolonged survival in patients with unresectable pancreatic cancer treated with the oestrogen antagonist agent tamoxifen (Theve et al, 1983;Tonnensen & KampJensen, 1986).…”
mentioning
confidence: 99%